Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here’s Why Novo Nordisk A/S (NVO) Slid in Q3
Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.
Pharmaceutical Technology6d
Liraglutide by Novo Nordisk for Alzheimer’s Disease: Likelihood of Approval
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
Pharmaceutical Technology6d
Ziltivekimab by Novo Nordisk for Myocardial Infarction: Likelihood of Approval
Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.